Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547228 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBEPHX1 | |
| SCHEMBL12811829 | 0.80 | EPHX1 (0.42) | KDM4EEPHX1 | |
| SCHEMBL2676319 | 0.79 | EPHX1 (0.49) | KDM4EEPHX1 | |
| SCHEMBL13547213 | 0.79 | EPHX1 (0.49) | KDM4EEPHX1 | |
| SCHEMBL13809020 | 0.77 | ALDH1A1 (0.34) | GAAPOLBEPHX1 | |
| SCHEMBL28663596 | 0.73 | EPHX1 (0.38) | POLBEPHX1 | |
| SCHEMBL12995653 | 0.72 | DRD2 (0.46) | GAAEPHX1 | |
| SCHEMBL13547356 | 0.71 | HTT (0.38) | KDM4EPOLBEPHX1 | |
| SCHEMBL13547225 | 0.70 | KDM4E (0.46) | KDM4EGAAEPHX1 | |
| SCHEMBL13547377 | 0.70 | KDM4E (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| WO-2008039420-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, SI, MGAM2 | KDM4E 2398/4885GAA 14/4885POLB 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.